Sarah B. Noonberg
CIK 1706301 · Chief Medical Officer · last filed 2026-02-24
Sarah B. Noonberg is a Chief Medical Officer who has filed 26 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing, for NGNE, was dated Feb 24, 2026. Across all open-market trades the lifetime net is −$221.7K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $638.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$638.4K
6
26
-$221.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NGNE | Director | — | $33.22 | — | $0 | 4 | 2026-02-24 |
| MGX | Chief Medical Officer | 109,135 | $1.21 | $132.1K | -$9.2K | 3 | 2025-06-09 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | 14,100 | $0.55 | $7.8K | $0 | 3 | 2024-06-20 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 5 | 2023-06-09 |
| PTGX | Director | 3,700 | $136.84 | $506.3K | -$212.6K | 9 | 2023-01-18 |
| PRTA | Chief Medical Officer | — | $8.56 | — | $0 | 1 | 2017-05-18 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-24 | NGNE | Grant (A) | — | $0 | EDGAR |
| 2025-09-11 | MGX | Notice (144) | −35,832 | -$68.1K | EDGAR |
| 2025-06-13 | NGNE | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | MGX | Sell (S) | −5,239 | -$9.2K | EDGAR |
| 2025-04-03 | MGX | Grant (A) | +14,000 | $0 | EDGAR |
| 2024-06-20 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | +2,300 | $0 | EDGAR |
| 2024-06-17 | NGNE | Grant (A) | — | $0 | EDGAR |
| 2024-04-03 | MGX | Grant (A) | +57,763 | $0 | EDGAR |
| 2024-01-19 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | +4,600 | $0 | EDGAR |
| 2024-01-18 | NGNE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.